For the quarter ending 2026-03-31, ENSCW made $960,999 in revenue. -$3,556,415 in net income. Net profit margin of -370.07%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Federal grants | 960,999 | 2,269,837* | 493,104 | 1,371,438 |
| Research and development | 3,346,881 | 3,059,137.5* | 2,954,909 | 1,923,430 |
| General and administrative | 1,176,348 | 1,213,981.5* | 1,279,290 | 1,198,523 |
| Total operating expenses | 4,523,229 | 4,273,119* | 4,234,199 | 3,121,953 |
| Loss from operations | -3,562,230 | -2,003,282* | -3,741,095 | -1,750,515 |
| Change in fair value of liability classified warrants | - | 9,878.5* | 998 | -853 |
| Interest expense, net | 3,923 | 4,473.5* | 6,369 | 3,160 |
| Other income and expense, net | 9,738 | 15,906.5* | 17,338 | 21,011 |
| Total other income (expense), net | 5,815 | 21,311.5* | 11,967 | 16,998 |
| Net loss | -3,556,415 | -1,981,970.5* | -3,729,128 | -1,733,517 |
| Deemed dividend related to warrants down round provision | - | - | - | 0 |
| Net gain attributable to noncontrolling interests | - | 11* | - | -166 |
| Net loss attributable to common stockholders | -3,556,415 | -1,981,981.5 | -3,729,128 | -1,733,351 |
| Basic EPS | -0.52 | -0.767 | -1.29 | -0.79 |
| Diluted EPS | -0.52 | -0.767 | -1.29 | -0.79 |
| Basic Average Shares | 6,839,385 | 2,583,773 | 2,886,059 | 2,202,299 |
| Diluted Average Shares | 6,839,385 | 2,583,773 | 2,886,059 | 2,202,299 |
Ensysce Biosciences, Inc. (ENSCW)
Ensysce Biosciences, Inc. (ENSCW)